Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.53B P/E - EPS this Y -2.50% Ern Qtrly Grth -
Income -374.93M Forward P/E -8.23 EPS next Y -10.50% 50D Avg Chg 31.00%
Sales 49.63M PEG -0.37 EPS past 5Y - 200D Avg Chg 55.00%
Dividend N/A Price/Book 5.88 EPS next 5Y 12.00% 52W High Chg -21.00%
Recommedations 2.70 Quick Ratio 5.54 Shares Outstanding 275.07M 52W Low Chg 190.00%
Insider Own 4.55% ROA -34.35% Shares Float 245.45M Beta 0.81
Inst Own 87.46% ROE -71.18% Shares Shorted/Prior 59.16M/54.15M Price 13.17
Gross Margin - Profit Margin - Avg. Volume 5,772,806 Target Price 9.44
Oper. Margin -697.39% Earnings Date Nov 7 Volume 4,541,377 Change -4.67%
About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Recursion Pharmaceuticals, Inc. News
12/21/24 Is Recursion Pharmaceuticals Stock a Millionaire Maker?
12/21/24 1 Artificial Intelligence (AI) Stock That Could Soar in 2025
12/20/24 Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
12/15/24 Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)
12/12/24 Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials
12/11/24 Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers
12/09/24 Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
12/04/24 Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘It Is Worthwhile Speculation’
12/03/24 Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
11/27/24 Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One
10:00 AM 2 Innovative Stocks That Could Deliver Outsize Returns
11/20/24 Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
11/15/24 Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes
11/13/24 Recursion and Exscientia Shareholders Approve the Proposed Combination
11/12/24 Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
11/10/24 Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher
11/06/24 Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
11/06/24 Recursion Pharmaceuticals: Q3 Earnings Snapshot
11/06/24 Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
11/02/24 Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Larson Tina Marriott President and COO President and COO Jan 25 Sell 10.35 8,000 82,800 414,548 01/29/24
Larson Tina Marriott President and COO President and COO Jan 25 Option 1.06 8,000 8,480 422,584 01/29/24
Borgeson Blake Director Director Jan 23 Sell 10.5756 20,054 212,083 7,324,364 01/25/24
Virani Shafique Chief Business Offic.. Chief Business Officer Jan 16 Sell 10.93 18,000 196,740 136,748 01/18/24
Virani Shafique Chief Business Offic.. Chief Business Officer Jan 16 Option 2.22 18,000 39,960 154,748 01/18/24
Secora Michael Chief Financial Offi.. Chief Financial Officer Jan 16 Sell 10.35 50,000 517,500 981,014 01/18/24
Secora Michael Chief Financial Offi.. Chief Financial Officer Jan 16 Option 2.22 75,000 166,500 1,006,014 01/18/24
Li Dean Y Director Director Jan 09 Sell 13.84 29,000 401,360 421,000 01/11/24
Borgeson Blake Director Director Jan 09 Sell 13.51 20,054 270,930 7,344,418 01/11/24
Gibson Christopher Chief Executive Offi.. Chief Executive Officer Jan 03 Sell 9.5 55,853 530,604 01/05/24
Gibson Christopher Chief Executive Offi.. Chief Executive Officer Jan 03 Option 2.48 31,250 77,500 822,578 01/05/24
Larson Tina Marriott President and COO President and COO Dec 28 Option 1.06 8,000 8,480 422,548 01/02/24
Larson Tina Marriott President and COO President and COO Dec 28 Sell 10.58 8,000 84,640 414,548 01/02/24
Borgeson Blake Director Director Dec 26 Sell 10.6285 20,054 213,144 7,364,472 12/28/23
Virani Shafique Chief Business Offic.. Chief Business Officer Dec 15 Sell 9.6 18,000 172,800 136,748 12/19/23
Virani Shafique Chief Business Offic.. Chief Business Officer Dec 15 Option 2.22 18,000 39,960 154,748 12/19/23
Dar Zavain Director Director Dec 14 Sell 9.00 20,141 181,269 53,823 12/18/23
Secora Michael Chief Financial Offi.. Chief Financial Officer Dec 12 Sell 7.49 50,000 374,500 956,014 12/14/23
Secora Michael Chief Financial Offi.. Chief Financial Officer Dec 12 Option 2.22 75,000 166,500 981,014 12/14/23
Borgeson Blake Director Director Dec 12 Sell 7.3987 11,447 84,693 7,384,526 12/14/23
Gibson Christopher Chief Executive Offi.. Chief Executive Officer Dec 06 Sell 7.49 59,829 448,119 791,328 12/08/23
Gibson Christopher Chief Executive Offi.. Chief Executive Officer Dec 06 Option 2.48 31,250 77,500 851,157 12/08/23
Borgeson Blake Director Director Nov 28 Sell 6.7195 11,447 76,918 7,395,973 11/30/23
Larson Tina Marriott President and COO President and COO Nov 15 Sell 6.76 3,000 20,280 413,404 11/17/23
Larson Tina Marriott President and COO President and COO Nov 15 Option 1.06 3,000 3,180 416,404 11/17/23
Virani Shafique Chief Business Offic.. Chief Business Officer Nov 15 Sell 6.51 18,000 117,180 140,351 11/17/23
Virani Shafique Chief Business Offic.. Chief Business Officer Nov 15 Option 2.22 18,000 39,960 158,351 11/17/23
Borgeson Blake Director Director Nov 14 Sell 6.3197 8,885 56,151 7,407,420 11/16/23
Secora Michael Chief Financial Offi.. Chief Financial Officer Nov 14 Sell 7.06 50,000 353,000 938,186 11/16/23
Secora Michael Chief Financial Offi.. Chief Financial Officer Nov 14 Option 2.22 75,000 166,500 963,186 11/16/23
Gibson Christopher Chief Executive Offi.. Chief Executive Officer Nov 01 Sell 5.15 62,177 320,212 11/03/23
Gibson Christopher Chief Executive Offi.. Chief Executive Officer Nov 01 Option 2.48 31,250 77,500 873,997 11/03/23
Borgeson Blake Director Director Oct 31 Sell 5.2745 8,885 46,864 7,416,305 11/02/23
Larson Tina Marriott President and COO President and COO Oct 26 Sell 5.63 3,000 16,890 418,782 10/30/23
Larson Tina Marriott President and COO President and COO Oct 26 Option 1.06 3,000 3,180 421,782 10/30/23
Borgeson Blake Director Director Oct 17 Sell 6.5822 8,885 58,483 7,425,190 10/19/23
Virani Shafique Chief Business Offic.. Chief Business Officer Oct 16 Sell 6.3 18,000 113,400 140,351 10/18/23
Virani Shafique Chief Business Offic.. Chief Business Officer Oct 16 Option 2.22 18,000 39,960 158,351 10/18/23
Secora Michael Chief Financial Offi.. Chief Financial Officer Oct 10 Sell 6.96 50,000 348,000 913,186 10/12/23
Secora Michael Chief Financial Offi.. Chief Financial Officer Oct 10 Option 2.22 75,000 166,500 938,186 10/12/23
Gibson Christopher Chief Executive Offi.. Chief Executive Officer Oct 04 Sell 7.21 59,794 431,115 842,747 10/06/23
Gibson Christopher Chief Executive Offi.. Chief Executive Officer Oct 04 Option 2.48 31,250 77,500 902,541 10/06/23
Borgeson Blake Director Director Oct 03 Sell 7.2907 8,885 64,778 7,434,075 10/05/23
Larson Tina Marriott President and COO President and COO Sep 28 Sell 7.72 3,000 23,160 418,782 10/02/23
Larson Tina Marriott President and COO President and COO Sep 28 Option 1.06 3,000 3,180 421,782 10/02/23
Borgeson Blake Director Director Sep 19 Sell 8.3599 8,885 74,278 7,442,960 09/21/23
Virani Shafique Chief Business Offic.. Chief Business Officer Sep 15 Sell 8.66 18,000 155,880 140,351 09/19/23
Virani Shafique Chief Business Offic.. Chief Business Officer Sep 15 Option 2.22 18,000 39,960 158,351 09/19/23
Secora Michael Chief Financial Offi.. Chief Financial Officer Sep 12 Sell 8.56 50,000 428,000 888,186 09/14/23
Secora Michael Chief Financial Offi.. Chief Financial Officer Sep 12 Option 2.22 75,000 166,500 913,186 09/14/23